<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Ding-Jie Lee 李定頡 | DLit-Hub</title>
    <link>http://localhost:1313/author/ding-jie-lee-%E6%9D%8E%E5%AE%9A%E9%A0%A1/</link>
      <atom:link href="http://localhost:1313/author/ding-jie-lee-%E6%9D%8E%E5%AE%9A%E9%A0%A1/index.xml" rel="self" type="application/rss+xml" />
    <description>Ding-Jie Lee 李定頡</description>
    <generator>Hugo Blox Builder (https://hugoblox.com)</generator><language>en-us</language><lastBuildDate>Fri, 29 Nov 2024 00:00:00 +0000</lastBuildDate>
    <image>
      <url>http://localhost:1313/author/ding-jie-lee-%E6%9D%8E%E5%AE%9A%E9%A0%A1/avatar_hu14417156126863153076.jpg</url>
      <title>Ding-Jie Lee 李定頡</title>
      <link>http://localhost:1313/author/ding-jie-lee-%E6%9D%8E%E5%AE%9A%E9%A0%A1/</link>
    </image>
    
    <item>
      <title>沈默的兇手：IgA腎病變</title>
      <link>http://localhost:1313/post/iga_nephropathy/</link>
      <pubDate>Fri, 29 Nov 2024 00:00:00 +0000</pubDate>
      <guid>http://localhost:1313/post/iga_nephropathy/</guid>
      <description>&lt;h2 id=&#34;quick-look&#34;&gt;Quick look&lt;/h2&gt;
&lt;p&gt;IgA腎病變(IgA nephropathy, IgAN)是一種常見的原發性腎小球腎炎，雖然進程緩慢，但仍有不少患者在會一生中面臨腎衰竭或是洗腎的風險。該疾病的致病機轉主要來自於黏膜免疫系統中衍生的缺半乳糖化IgA1在血液中濃度升高，且和特異性IgG和IgA抗體結合，形成免疫複合物沉積於腎小球內，導致發炎、補體活化及腎損傷。儘管現有的治療選擇有限，但針對不同途徑的療法(如腸道黏膜B細胞、APRIL和BAFF細胞因子、漿細胞及補體系統的活化)正在快速發展，本篇針對最新發表在nature review nephrology的&lt;a href=&#34;https://www.nature.com/articles/s41581-024-00885-3&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;文章&lt;/a&gt;，深入探討IgAN的病生理機制與治療前景。&lt;/p&gt;
&lt;h1 id=&#34;前情提要&#34;&gt;前情提要&lt;/h1&gt;
&lt;ol&gt;
&lt;li&gt;IgAN最早於1968年由Jean Berger與Nicole Hinglais提出，其特徵為腎小球間質中出現IgA沉積。&lt;/li&gt;
&lt;li&gt;IgA腎病與IgA血管炎在腎臟病理學上無法區分，但後者會影響其他器官如皮膚、關節、胃腸道。&lt;/li&gt;
&lt;li&gt;IgAN的年發病率估計為每10萬成年人中至少2.5例，實際數據因不同因素而被低估。&lt;/li&gt;
&lt;li&gt;患病率有明顯的地域差別(圖一)：東亞地區高達40-50%，而北美、歐洲分別為10-20%及20%，而非洲則少於5%。男性患者比例在歐美地區明顯偏高(約2:1)，亞洲則為1:1。&lt;/li&gt;
&lt;li&gt;雖然部分患者病程較為良性，但大多數患者需要長期治療以減緩腎功能下降，現有標準治療對疾病的控制有限。&lt;/li&gt;
&lt;li&gt;IgAN對患者及其家庭，以及全球各地的醫療體系帶來重大負擔。因此開發安全且有效的長期療法刻不容緩。&lt;/li&gt;
&lt;/ol&gt;
&lt;p&gt;















&lt;figure  id=&#34;figure-圖一&#34;&gt;
  &lt;div class=&#34;d-flex justify-content-center&#34;&gt;
    &lt;div class=&#34;w-100&#34; &gt;&lt;img alt=&#34;fig1&#34; srcset=&#34;
               /post/iga_nephropathy/fig1_hu8477814647956072909.webp 400w,
               /post/iga_nephropathy/fig1_hu2347947302523353437.webp 760w,
               /post/iga_nephropathy/fig1_hu16276878206001251811.webp 1200w&#34;
               src=&#34;http://localhost:1313/post/iga_nephropathy/fig1_hu8477814647956072909.webp&#34;
               width=&#34;760&#34;
               height=&#34;390&#34;
               loading=&#34;lazy&#34; data-zoomable /&gt;&lt;/div&gt;
  &lt;/div&gt;&lt;figcaption&gt;
      圖一
    &lt;/figcaption&gt;&lt;/figure&gt;
&lt;/p&gt;
&lt;h1 id=&#34;造成igan的關鍵何謂多打擊假說&#34;&gt;造成IgAN的關鍵?何謂多打擊假說?&lt;/h1&gt;
&lt;p&gt;即使我們知道IgA1抗體鉸鏈區(hinge region)上O-glycan側鏈若缺少半乳糖(galactose)，也稱為galactose deficient IgA1(Gd-IgA1)是IgAN的主要根源，但光有這個變異還不夠，因為IgAN病人的一級親屬即使在血液中有高濃度的血清Gd-IgA1，也不一定會發病。而目前研究顯示，要導致IgAN，至少需要四個事件的發生(&lt;strong&gt;不一定是獨立事件&lt;/strong&gt;)，才會產生臨床症狀並診斷為IgAN(圖二):&lt;/p&gt;
&lt;ol&gt;
&lt;li&gt;血液中出現Gd-IgA1(Hit1)。&lt;/li&gt;
&lt;li&gt;血液中出現對抗Gd-IgA1的IgA或IgG自體免疫球蛋白(Hit2)。&lt;/li&gt;
&lt;li&gt;Gd-IgA1會聚集在一起，吸引其他血清蛋白，並聯合自體免疫球蛋白形成免疫複合體(Immune complex)(Hit3)。&lt;/li&gt;
&lt;li&gt;繫膜細胞(mesangial cell)增生及堆積，並對腎絲球產生損傷(Hit 4)。&lt;/li&gt;
&lt;/ol&gt;
&lt;p&gt;而繫膜細胞的堆積會導致細胞激素(cytokine)的分泌、補體(complement)的活化、足細胞(podocyte)損傷、腎絲球過濾出問體等等，從血尿、蛋白尿、腎小管纖維化，進展到最終腎功能的喪失。&lt;/p&gt;
&lt;p&gt;















&lt;figure  id=&#34;figure-圖二&#34;&gt;
  &lt;div class=&#34;d-flex justify-content-center&#34;&gt;
    &lt;div class=&#34;w-100&#34; &gt;&lt;img alt=&#34;fig2&#34; srcset=&#34;
               /post/iga_nephropathy/fig2_hu9214946873256410068.webp 400w,
               /post/iga_nephropathy/fig2_hu8460772400180790820.webp 760w,
               /post/iga_nephropathy/fig2_hu1227887210895014429.webp 1200w&#34;
               src=&#34;http://localhost:1313/post/iga_nephropathy/fig2_hu9214946873256410068.webp&#34;
               width=&#34;760&#34;
               height=&#34;322&#34;
               loading=&#34;lazy&#34; data-zoomable /&gt;&lt;/div&gt;
  &lt;/div&gt;&lt;figcaption&gt;
      圖二
    &lt;/figcaption&gt;&lt;/figure&gt;
&lt;/p&gt;
&lt;h1 id=&#34;iga的抗體分型有什麼其妙之處&#34;&gt;IgA的抗體分型有什麼其妙之處？&lt;/h1&gt;
&lt;p&gt;IgA有兩種分型，以有無延伸的鉸鏈區來區分為IgA1及IgA2。IgA大多由黏膜淋巴組織(mucosa-associated lymphoid tissue, MALT)分秘，其中腸道淋巴組織(gut-associated lymphoid tissue, GALT)為IgA的主要來源。&lt;/p&gt;
&lt;p&gt;而IgA到底扮演了什麼角色？當腸道出現非共生(commensal)的病原時，腸道中的巨噬細胞或是M細胞會將抗原呈現給T細胞，間接或是直接刺激黏膜下的B細胞產生抗體，而產生抗體的過程需要一些協同的刺激訊號，其中細胞激素B cell activating factor(BAFF)及a proliferation-inducing ligand(APRIL)在獨立於T細胞(T cell independent)的抗體刺激中扮演了關鍵的角色。此時活化的B細胞不會馬上在黏膜下分秘IgA，而是再跑到中心的淋巴結進行進一步的變化：&lt;/p&gt;
&lt;ol&gt;
&lt;li&gt;IgA+ B細胞從MALT離開，經由淋巴系統和循環系統遷移至中央淋巴結，在那裡進一步分化。&lt;/li&gt;
&lt;li&gt;IgA+ B細胞回到黏膜固有層，在那裡成熟為分泌抗體的漿細胞(plasma cells)。&lt;/li&gt;
&lt;li&gt;漿細胞主要分泌聚合型IgA(pIgA），這種分子形式由至少兩個IgA單體通過&lt;strong&gt;J鏈&lt;/strong&gt;連接而成，J鏈是一種17kDa的蛋白，通過二硫鍵將α-重鏈上的半胱氨酸殘基連接。&lt;/li&gt;
&lt;li&gt;pIgA在黏膜上皮細胞的基底外側表面與聚合型Ig受體(pIgR)結合，並進行跨細胞移動至管腔面。&lt;/li&gt;
&lt;li&gt;在黏膜表面，pIgR被酶切割，其中一部分受體仍與pIgA結合，成為分泌成分，從而形成分泌型IgA(sIgA)。&lt;/li&gt;
&lt;/ol&gt;
&lt;p&gt;需要注意的是，這邊分秘的IgA為antigen-specific，會在腸道免疫反應發生後於循環中上升，與本來在循環中的單體IgA不同(由骨髓B細胞分秘)。由此可見IgA的分泌是系統性免疫反應中很重要的一部分。&lt;/p&gt;
&lt;h1 id=&#34;iga1鉸鏈區的混亂&#34;&gt;IgA1鉸鏈區的混亂？&lt;/h1&gt;
&lt;p&gt;在IgA1分子中，有一個特別的結構叫做鉸鏈區域，位於α重鏈的第一和第二區之間。這裡有18個氨基酸，可以進行轉譯後的修飾，在蘇胺酸(threonine)及絲胺酸(serine)上加上一個糖基(圖三)。而這項修飾目的是要防止微生物蛋白酶對這個區域進行降解。&lt;/p&gt;
&lt;p&gt;在IgA1分子中，9個潛在的糖基化位點中通常有3到6個會被修飾：&lt;/p&gt;
&lt;ol&gt;
&lt;li&gt;由N-乙醯半乳糖胺轉移酶2(&lt;strong&gt;GalNAcT2&lt;/strong&gt;)添加N-乙醯半乳糖胺(&lt;strong&gt;GalNAc&lt;/strong&gt;)。&lt;/li&gt;
&lt;li&gt;核心1β-1,3-半乳糖基轉移酶(&lt;strong&gt;C1GalT1&lt;/strong&gt;)在輔助下，將半乳糖與GalNAc結合，完成主要的修飾。&lt;/li&gt;
&lt;li&gt;唾液酸(&lt;strong&gt;Sialic acid&lt;/strong&gt;)被加入，為分子提供更強的防護，防止後續修飾。&lt;/li&gt;
&lt;/ol&gt;
&lt;p&gt;其實，微生物的影響也不可忽視，一些微生物釋放的PAMPs(Pathogen-associated molecular patterns)會促使IgA1半乳糖化的程度減少，讓鉸鏈區對微生物蛋白酶失去招架的能力。&lt;/p&gt;
&lt;p&gt;為什麼會出現這些異常？研究發現，基因的因素及腸道黏膜的環境都有可能造成C1GalT1活性下降或是GalNAc唾液酸化的增加，都會減少半乳糖化，促使更多的Gd-IgA1產生。&lt;/p&gt;
&lt;p&gt;半乳糖化的程度減少似乎沒有想像中的可怕，但可怕的是Gd-IgA1會有和彼此之間形成聚合物的傾向，並和一堆血清蛋白結合。這種狀況下產生的免疫複合物還會激活補體系統，誘發一連串的發炎反應。&lt;/p&gt;
&lt;p&gt;















&lt;figure  id=&#34;figure-圖三&#34;&gt;
  &lt;div class=&#34;d-flex justify-content-center&#34;&gt;
    &lt;div class=&#34;w-100&#34; &gt;&lt;img alt=&#34;fig3&#34; srcset=&#34;
               /post/iga_nephropathy/fig3_hu17316065617603901825.webp 400w,
               /post/iga_nephropathy/fig3_hu3953366864811020813.webp 760w,
               /post/iga_nephropathy/fig3_hu2584949262212506169.webp 1200w&#34;
               src=&#34;http://localhost:1313/post/iga_nephropathy/fig3_hu17316065617603901825.webp&#34;
               width=&#34;760&#34;
               height=&#34;586&#34;
               loading=&#34;lazy&#34; data-zoomable /&gt;&lt;/div&gt;
  &lt;/div&gt;&lt;figcaption&gt;
      圖三
    &lt;/figcaption&gt;&lt;/figure&gt;
&lt;/p&gt;
&lt;h1 id=&#34;源源不絕的gd-iga1&#34;&gt;源源不絕的Gd-IgA1&lt;/h1&gt;
&lt;p&gt;Gd-IgA1的來源可能涉及兩個主要的來源：黏膜和骨髓。目前許多證據支持黏膜是主要來源，因為IgAN的病情嚴重程度與黏膜感染密切相關。例如，在小鼠模型中，使用廣效抗生素清除腸道菌群可以有效防止IgA在腎絲球中的沉積。而在另一項實驗中(針對 BAFF過表達小鼠，這類小鼠會產生自發性類IgAN疾病)，將小鼠飼養於無菌環境下，能有效阻止腎絲球IgA的沉積。此外，研究發現IgAN患者在上呼吸道感染時，循環中的IgA+B細胞數量顯著增加，進一步支持黏膜作為Gd-IgA1主要來源的假說。&lt;/p&gt;
&lt;p&gt;黏膜來源的IgA1常為聚合型，且O-糖基化不足，與IgAN患者循環中以及腎絲球中沉積的Gd-IgA1極為相似。然而，一些黏膜衍生的B細胞可&lt;strong&gt;錯位&lt;/strong&gt;至骨髓，並在那裡產生致病性Gd-IgA1。與健康人相比，IgAN患者骨髓中含有比例更高的漿細胞，這些細胞能分泌二聚體(dimeric)IgA1。總結來說，黏膜和骨髓都可能是病理性IgA的重要來源。&lt;/p&gt;
&lt;h1 id=&#34;免疫複合體集結&#34;&gt;免疫複合體集結！&lt;/h1&gt;
&lt;p&gt;IgAN患者的病理性Gd-IgA1主要以高分子量免疫複合物形式存在，這些複合物由抗Gd-IgA1的IgG或IgA抗體結合而成，其形成與遺傳因素(如HLA多型性)和環境因素密切相關。在環境因素的部分，&lt;/p&gt;
&lt;p&gt;這些免疫複合物在腎絲球中的沉積會激活腎間質細胞，導致發炎和增殖，並通過補體系統加重腎臟的破壞。同時，這些複合物因其結構特性導致肝臟清除功能受限，進一步促使其累積並讓IgAN惡化。此外，IgA1–sCD89複合物的生成和作用在疾病中可能也具有重要意義，但其具體機制仍需進一步研究。&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>新文章發表於 European Urology</title>
      <link>http://localhost:1313/event/meta_publish/</link>
      <pubDate>Wed, 11 Sep 2024 00:00:00 +0000</pubDate>
      <guid>http://localhost:1313/event/meta_publish/</guid>
      <description>&lt;h1 id=&#34;title&#34;&gt;Title&lt;/h1&gt;
&lt;p&gt;A Meta-Analysis and Meta-Regression of the Efficacy, Toxicity, and Quality of Life Outcomes Following Prostate-Specific Membrane Antigen Radioligand Therapy Utilising Lutetium-177 and Actinium- 225 in Metastatic Prostate Cancer&lt;/p&gt;
&lt;h1 id=&#34;abstract&#34;&gt;Abstract&lt;/h1&gt;
&lt;p&gt;Background and objective: Management of metastatic prostate cancer (mPCa) presents significant challenges. In this systematic review, meta-analysis, and meta-regression, the efficacy, safety, and quality of life (QoL) outcomes of prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (PRLT) utilising lutetium-177 ([177Lu]Lu-PSMA) and actinium-225 ([225Ac]Ac-PSMA) were assessed.&lt;/p&gt;
&lt;p&gt;Methods:
A detailed literature search across PubMed/Medline, EMBASE, Web of Science, Scopus, and Cochrane Library was conducted, culminating in the inclusion of 100 studies involving 8711 patients. Data on prostate-specific antigen (PSA) responses, toxicity profiles, and QoL and survival outcomes were analysed. Proportional meta-analyses and meta-regression analyses were performed.&lt;/p&gt;
&lt;p&gt;Key findings and limitations:
The estimated proportion of patients with PSA decline ≥50% was 0.49 for [177Lu]Lu-PSMA and 0.60 for [225Ac]Ac-PSMA in mPCa, particularly metastatic castration-resistant prostate cancer. A meta-regression analysis indicated an association between the cumulative amount of administered activity and the proportion of PSA ≥50% decline. Positive PSA responses were observed alongside improved overall survival across both therapies. Our analyses also identified the key factors associated with PSA responses and survival outcomes, including baseline haemoglobin level, and the presence of visceral metastases. Although anaemia was commonly observed, with [177Lu]Lu-PSMA, severe toxicities were infrequent. Improved QoL was observed following [177Lu]Lu-PSMA therapy, whereas it remained stable following the second cycle of [225Ac]Ac-PSMA treatment. Heterogeneity across studies for PSA responses and toxicity profiles is a limitation.&lt;/p&gt;
&lt;p&gt;Conclusions and clinical implications:
Our findings suggest an association between PRLT and reductions in PSA levels, as well as associations with enhanced survival outcomes in mPCa. Furthermore, our analysis shows a low incidence of severe toxicity associated with this treatment. These observations highlight the important role of PRLT in the management of mPCa.&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>腎臟科國考複習</title>
      <link>http://localhost:1313/event/example/</link>
      <pubDate>Wed, 07 Feb 2024 00:00:00 +0000</pubDate>
      <guid>http://localhost:1313/event/example/</guid>
      <description>

    
    &lt;div style=&#34;position: relative; padding-bottom: 56.25%; height: 0; overflow: hidden;&#34;&gt;
      &lt;iframe allow=&#34;accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share&#34; allowfullscreen=&#34;allowfullscreen&#34; loading=&#34;eager&#34; referrerpolicy=&#34;strict-origin-when-cross-origin&#34; src=&#34;https://www.youtube.com/embed/bVHMlVoop68?autoplay=0&amp;controls=1&amp;end=0&amp;loop=0&amp;mute=0&amp;start=0&#34; style=&#34;position: absolute; top: 0; left: 0; width: 100%; height: 100%; border:0;&#34; title=&#34;YouTube video&#34;
      &gt;&lt;/iframe&gt;
    &lt;/div&gt;

</description>
    </item>
    
    <item>
      <title>新文章發表於Journal of Translational Medicine</title>
      <link>http://localhost:1313/event/lupus/</link>
      <pubDate>Fri, 03 Feb 2023 00:00:00 +0000</pubDate>
      <guid>http://localhost:1313/event/lupus/</guid>
      <description>&lt;h1 id=&#34;title&#34;&gt;Title&lt;/h1&gt;
&lt;p&gt;Incorporating knowledge of disease-defining hub genes and regulatory network into a machine learning-based model for predicting treatment response in lupus nephritis after the first renal flare&lt;/p&gt;
&lt;h1 id=&#34;abstract&#34;&gt;Abstract&lt;/h1&gt;
&lt;p&gt;Background:Identifying candidates responsive to treatment is important in lupus nephritis (LN) at the renal flare (RF) because an effective treatment can lower the risk of progression to end-stage kidney disease. However, machine learning (ML)-based models that address this issue are lacking.&lt;/p&gt;
&lt;p&gt;Methods:Transcriptomic profiles based on DNA microarray data were extracted from the GSE32591 and GSE112943 datasets. Comprehensive bioinformatics analyses were performed to identify disease-defining genes (DDGs). Peripheral blood samples (GSE81622, GSE99967, and GSE72326) were used to evaluate the effect of DDGs. Single-sample gene set enrichment analysis (ssGSEA) scores of the DDGs were calculated and correlated with specific immunology genes listed in the nCounter panel. GSE60681 and GSE69438 were used to examine the ability of the DDGs to discriminate LN from other renal diseases. K-means clustering was used to obtain the separate gene sets. The clustering results were extended to data derived using the nCounter technique. The least absolute shrinkage and selection operator (LASSO) algorithm was used to identify genes with high predictive value for treatment response after the first RF in each cluster. LASSO models with tenfold validation were built in GSE200306 and assessed by receiver operating characteristic (ROC) analysis with area under curve (AUC). The models were validated by using an independent dataset (GSE113342).&lt;/p&gt;
&lt;p&gt;Results:Forty-five hub genes specific to LN were identified. Eight optimal disease-defining clusters (DDCs) were identified in this study. Th1 and Th2 cell differentiation pathway was significantly enriched in DDC-6. LCK in DDC-6, whose expression positively correlated with various subsets of T cell infiltrations, was found to be differentially expressed between responders and non-responders and was ranked high in regulatory network analysis. Based on DDC-6, the prediction model had the best performance (AUC: 0.75; 95% confidence interval: 0.44–1 in the testing set) and high precision (0.83), recall (0.71), and F1 score (0.77) in the validation dataset.&lt;/p&gt;
&lt;p&gt;Conclusions:Our study demonstrates that incorporating knowledge of biological phenotypes into the ML model is feasible for evaluating treatment response after the first RF in LN. This knowledge-based incorporation improves the model&amp;rsquo;s transparency and performance. In addition, LCK may serve as a biomarker for T-cell infiltration and a therapeutic target in LN.&lt;/p&gt;
</description>
    </item>
    
  </channel>
</rss>
